HUE050733T2 - Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék - Google Patents
Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermékInfo
- Publication number
- HUE050733T2 HUE050733T2 HUE13779378A HUE13779378A HUE050733T2 HU E050733 T2 HUE050733 T2 HU E050733T2 HU E13779378 A HUE13779378 A HU E13779378A HU E13779378 A HUE13779378 A HU E13779378A HU E050733 T2 HUE050733 T2 HU E050733T2
- Authority
- HU
- Hungary
- Prior art keywords
- propylimino
- dihydroxypropoxy
- thiazolidin
- benzylidene
- tolyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/77—Preparation of chelates of aldehydes or ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
- C07C45/81—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12180920 | 2012-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE050733T2 true HUE050733T2 (hu) | 2021-01-28 |
Family
ID=46940231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13779378A HUE050733T2 (hu) | 2012-08-17 | 2013-08-15 | Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9340518B2 (hu) |
| EP (1) | EP2885266B1 (hu) |
| JP (2) | JP6322630B2 (hu) |
| KR (1) | KR101731739B1 (hu) |
| CN (1) | CN104540800B (hu) |
| CA (1) | CA2895172C (hu) |
| CY (1) | CY1123300T1 (hu) |
| DK (1) | DK2885266T3 (hu) |
| ES (1) | ES2795105T3 (hu) |
| HR (1) | HRP20200883T1 (hu) |
| HU (1) | HUE050733T2 (hu) |
| IL (1) | IL237198A (hu) |
| LT (1) | LT2885266T (hu) |
| MX (1) | MX350891B (hu) |
| PL (1) | PL2885266T3 (hu) |
| PT (1) | PT2885266T (hu) |
| RS (1) | RS60408B1 (hu) |
| SI (1) | SI2885266T1 (hu) |
| TW (1) | TWI606036B (hu) |
| WO (1) | WO2014027330A1 (hu) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2278960T (pt) | 2008-03-17 | 2017-03-09 | Actelion Pharmaceuticals Ltd | Regime de dosagem para um agonista seletivo do recetor s1p1 |
| PT2885266T (pt) * | 2012-08-17 | 2020-05-29 | Actelion Pharmaceuticals Ltd | Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| PL3256125T3 (pl) | 2014-12-11 | 2022-05-09 | Actelion Pharmaceuticals Ltd | Schemat dawkowania ponesimodu, selektywnego agonisty receptora s1p1 |
| CA3009713A1 (en) * | 2015-12-25 | 2017-06-29 | Crystal Pharmatech Co., Ltd. | Crystalline forms of ponesimod and preparation method thereof |
| JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| WO2019060147A1 (en) * | 2017-09-19 | 2019-03-28 | Teva Pharmaceuticals Usa, Inc. | NEW CRYSTALLINE POLYMORPHE FROM PONESIMOD |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| KR102365655B1 (ko) | 2018-11-29 | 2022-02-22 | 원광대학교 산학협력단 | 콩 발효 추출물을 유효성분으로 포함하는 피부 주름 예방 또는 개선용 조성물 |
| CA3156298A1 (en) | 2019-10-31 | 2021-05-06 | Laetitia POUZOL | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
| WO2023022896A1 (en) | 2021-08-17 | 2023-02-23 | Teva Czech Industries S.R.O | Polymorphs of ponesimod |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| WO2023152691A1 (en) * | 2022-02-10 | 2023-08-17 | Metrochem Api Pvt Ltd | Process for the preparation of ponesimod and its intermediates thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3077402A (en) | 1954-12-06 | 1963-02-12 | Polaroid Corp | Photographic color processes, products, and compositions |
| NL270002A (hu) | 1960-10-08 | |||
| GB1001479A (en) | 1962-10-10 | 1965-08-18 | Angeli Inst Spa | Glycerol ethers |
| OA03835A (fr) | 1970-07-17 | 1971-12-24 | Rhone Poulenc Sa | Nouveaux dérivés de la thiazolidine, leur préparation et les compositions qui les contiennent. |
| HU214872B (hu) | 1990-04-27 | 1998-07-28 | Orion-Yhtymä Oy | Eljárás farmakológiailag aktív új katecholszármazékok és ezeket tartalmazó gyógyászati készítmények előállítására |
| TW221689B (hu) | 1991-08-27 | 1994-03-11 | Otsuka Pharma Co Ltd | |
| CA2134347C (en) | 1993-02-26 | 2003-04-29 | Koichi Yasumura | Thiazole or imidazole derivatives as maillard reaction inhibitors |
| KR960022486A (ko) | 1994-12-29 | 1996-07-18 | 김준웅 | 신규 티아졸리딘-4-온 유도체 |
| US6353006B1 (en) | 1999-01-14 | 2002-03-05 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| JP3936189B2 (ja) | 1999-09-14 | 2007-06-27 | 塩野義製薬株式会社 | ２−イミノ−１，３−チアジン誘導体 |
| ATE345332T1 (de) | 1999-11-12 | 2006-12-15 | Fujimoto Brothers Co Ltd | 2-(n-cyanimino)thiazolidin-4-on derivate |
| US20050019825A9 (en) | 2002-03-15 | 2005-01-27 | Qing Dong | Common ligand mimics: pseudothiohydantoins |
| CN1681811B (zh) | 2002-07-10 | 2010-05-26 | 默克雪兰诺有限公司 | 唑烷酮-乙烯基稠合的-苯衍生物 |
| GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| AU2003261434A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
| NZ539873A (en) | 2002-11-22 | 2008-09-26 | Smithkline Beecham Corp | Novel chemical compounds, thiazolidin-4-one, thiazol-4-one |
| US20040167192A1 (en) | 2003-01-16 | 2004-08-26 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
| EP1667791A1 (en) | 2003-10-06 | 2006-06-14 | Solvias AG | Process for the parallel detection of crystalline forms of molecular solids |
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| BRPI0416752B8 (pt) | 2003-11-21 | 2021-05-25 | Actelion Pharmaceuticals Ltd | composição farmacêutica, uso de um ou mais compostos, e, compostos |
| US20070249599A1 (en) | 2004-02-25 | 2007-10-25 | Duffy Kevin J | Novel Chemical Compounds |
| WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| MX2007006373A (es) | 2004-11-29 | 2007-06-20 | Novartis Ag | Regimen de dosificacion de un agonista del receptor s1p. |
| WO2006094233A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N,n'-dicyclic isothiourea sirtuin modulators |
| CA2602478A1 (en) | 2005-03-23 | 2006-09-28 | Actelion Pharmaceuticals Ltd | Novel thiophene derivatives |
| KR101382733B1 (ko) | 2005-03-23 | 2014-04-14 | 액테리온 파마슈티칼 리미티드 | 면역조절물질로서의 수첨 벤조(ｃ) 티오펜 유도체 |
| KR20070116645A (ko) | 2005-03-23 | 2007-12-10 | 액테리온 파마슈티칼 리미티드 | 스핑고신-1-포스페이트-1 수용체 길항제로서의 신규한티오펜 유도체 |
| KR20080024533A (ko) | 2005-06-24 | 2008-03-18 | 액테리온 파마슈티칼 리미티드 | 신규한 티오펜 유도체 |
| AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
| TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| EP1979345B1 (en) | 2006-01-24 | 2009-11-04 | Actelion Pharmaceuticals Ltd. | Novel pyridine derivatives |
| US7879821B2 (en) | 2006-01-26 | 2011-02-01 | University Of Medicine And Dentistry Of New Jersey | Method for modulating inflammatory responses by altering plasma lipid levels |
| MX2009002233A (es) | 2006-09-07 | 2009-03-16 | Actelion Pharmaceuticals Ltd | Derivados de piridin-4-il como agentes inmunomoduladores. |
| AR061841A1 (es) | 2006-09-07 | 2008-09-24 | Actelion Pharmaceuticals Ltd | Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores. |
| KR101454937B1 (ko) | 2006-09-08 | 2014-10-27 | 액테리온 파마슈티칼 리미티드 | 면역조절제로서 피리딘-3-일 유도체 |
| US8044076B2 (en) | 2006-09-21 | 2011-10-25 | Actelion Pharmaceuticals Ltd. | Phenyl derivatives and their use as immunomodulators |
| EP2489662B1 (en) | 2006-11-23 | 2014-08-06 | Actelion Pharmaceuticals Ltd. | Intermediates of a new process for the preparation of 5-benzylidene-2-alkylimino-3-phenylthiazolidin-4-one derivatives |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| EP2125797B1 (en) | 2007-03-16 | 2014-01-15 | Actelion Pharmaceuticals Ltd. | Amino- pyridine derivatives as s1p1 /edg1 receptor agonists |
| WO2009024905A1 (en) | 2007-08-17 | 2009-02-26 | Actelion Pharmaceuticals Ltd | Pyridine derivatives as s1p1/edg1 receptor modulators |
| PT2278960T (pt) | 2008-03-17 | 2017-03-09 | Actelion Pharmaceuticals Ltd | Regime de dosagem para um agonista seletivo do recetor s1p1 |
| GB0819182D0 (en) * | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| EP2370438A1 (en) * | 2008-12-04 | 2011-10-05 | Exelixis, Inc. | Imidazo [1,2a]pyridine derivatives, their use as s1p1 agonists and methods for their production |
| PT2379069E (pt) | 2008-12-22 | 2015-07-03 | Novartis Ag | Inalador |
| DK3453387T3 (da) | 2008-12-22 | 2020-08-10 | Novartis Ag | Doseringsplan til en s1p-receptoragonist |
| PT2885266T (pt) * | 2012-08-17 | 2020-05-29 | Actelion Pharmaceuticals Ltd | Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo |
-
2013
- 2013-08-15 PT PT137793782T patent/PT2885266T/pt unknown
- 2013-08-15 CA CA2895172A patent/CA2895172C/en active Active
- 2013-08-15 LT LTEP13779378.2T patent/LT2885266T/lt unknown
- 2013-08-15 US US14/422,167 patent/US9340518B2/en active Active
- 2013-08-15 EP EP13779378.2A patent/EP2885266B1/en active Active
- 2013-08-15 RS RS20200642A patent/RS60408B1/sr unknown
- 2013-08-15 DK DK13779378.2T patent/DK2885266T3/da active
- 2013-08-15 CN CN201380042658.2A patent/CN104540800B/zh active Active
- 2013-08-15 PL PL13779378T patent/PL2885266T3/pl unknown
- 2013-08-15 HU HUE13779378A patent/HUE050733T2/hu unknown
- 2013-08-15 WO PCT/IB2013/056662 patent/WO2014027330A1/en active Application Filing
- 2013-08-15 KR KR1020157006474A patent/KR101731739B1/ko active IP Right Grant
- 2013-08-15 SI SI201331742T patent/SI2885266T1/sl unknown
- 2013-08-15 ES ES13779378T patent/ES2795105T3/es active Active
- 2013-08-15 JP JP2015527061A patent/JP6322630B2/ja active Active
- 2013-08-15 MX MX2015002127A patent/MX350891B/es active IP Right Grant
- 2013-08-16 TW TW102129570A patent/TWI606036B/zh active
-
2015
- 2015-02-12 IL IL237198A patent/IL237198A/en active IP Right Grant
-
2017
- 2017-04-13 JP JP2017079804A patent/JP6424250B2/ja active Active
-
2020
- 2020-06-02 HR HRP20200883TT patent/HRP20200883T1/hr unknown
- 2020-06-11 CY CY20201100532T patent/CY1123300T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104540800A (zh) | 2015-04-22 |
| MX350891B (es) | 2017-09-22 |
| WO2014027330A1 (en) | 2014-02-20 |
| EP2885266B1 (en) | 2020-03-18 |
| JP6322630B2 (ja) | 2018-05-09 |
| JP6424250B2 (ja) | 2018-11-14 |
| US9340518B2 (en) | 2016-05-17 |
| CY1123300T1 (el) | 2021-12-31 |
| EP2885266A1 (en) | 2015-06-24 |
| HRP20200883T1 (hr) | 2020-09-04 |
| JP2017160223A (ja) | 2017-09-14 |
| PT2885266T (pt) | 2020-05-29 |
| US20150203459A1 (en) | 2015-07-23 |
| MX2015002127A (es) | 2015-05-11 |
| CA2895172A1 (en) | 2014-02-20 |
| TWI606036B (zh) | 2017-11-21 |
| ES2795105T3 (es) | 2020-11-20 |
| CA2895172C (en) | 2020-08-18 |
| KR101731739B1 (ko) | 2017-05-11 |
| TW201408634A (zh) | 2014-03-01 |
| RS60408B1 (sr) | 2020-07-31 |
| PL2885266T3 (pl) | 2020-11-16 |
| JP2015530373A (ja) | 2015-10-15 |
| KR20150042277A (ko) | 2015-04-20 |
| IL237198A0 (en) | 2015-04-30 |
| IL237198A (en) | 2017-12-31 |
| LT2885266T (lt) | 2020-07-10 |
| DK2885266T3 (da) | 2020-06-08 |
| SI2885266T1 (sl) | 2020-10-30 |
| CN104540800B (zh) | 2017-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2885266T3 (pl) | Sposób otrzymywania (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroksypropoksy)benzylideno)-2-(propyloimino)-3-(o-tolilo)tiazolidyn-4-onu i produktu pośredniego stosowanego w tym sposobie | |
| IL281024A (en) | Pharmaceutical preparations containing N–(3,5–DIMETHOXYPHENYL)–N'–(1–METHYLETHYL)–N–[3–(1–METHYL–1H–PYRAZOL–4–YL)QUINOXALIN–6–YL]ETHANE–1, 2-DIAMINE | |
| IL260297A (en) | Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide | |
| IL245882B (en) | Process for the preparation of n-[(3-aminooxetane-3-yl)methyl]-2-(1,1-dioxo-5,3-dihydro-4,1-benzothiazepine-4-yl)-6-methyl-quinazoline- 4-Amin | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112014010179A8 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| EP3292119A4 (en) | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | |
| BR112013022523A2 (pt) | uso de glicopirrolato para o tratamento de taquicardia | |
| ZA201900640B (en) | Compound for use in the treatment of neurogenic orthostatic hypotension | |
| EP3175851A4 (en) | Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition | |
| HRP20220264T8 (hr) | Proces za pripremanje n-((1r,2s,sr)-5-(terc-butilamino)-2-((s)-3-(7-terc-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oksopirolidin-1-il)cikloheksil)acetamida | |
| BR112015001169A2 (pt) | polimorfo, uso do polimorfo, composição farmacêutica e uso para preparar o polimorfo | |
| EP3461823A4 (en) | PLX3397 HYDROCHLORIDE CRYSTAL FORM, MANUFACTURING METHOD AND USE THEREOF | |
| ZA201603729B (en) | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine | |
| PT3256109T (pt) | Composições farmacêuticas compreendendo n-(3,5-dimetoxifenil)-n¿-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina | |
| EP3436009A4 (en) | NEGATIVE ALLOSTERIC MODULATORS OF MGLUR5 USEFUL IN THE TREATMENT OF MATURE BRAIN LESIONS | |
| HUP1400105A2 (hu) | Nanostrukturált ibuprofent, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra | |
| TH122396B (th) | สารยึดติดแบบสารกระจายตัวชนิดใหม่, กรรมวิธีสำหรับเตรียมสารเหล่านั้น และการใช้ของสารนั้น |